

# Meredith S Irwin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3569747/publications.pdf>

Version: 2024-02-01

114  
papers

7,745  
citations

81900

39  
h-index

53230

85  
g-index

117  
all docs

117  
docs citations

117  
times ranked

11347  
citing authors

#	ARTICLE	IF	CITATIONS
1	Akt Phosphorylates the Yes-Associated Protein, YAP, to Induce Interaction with 14-3-3 and Attenuation of p73-Mediated Apoptosis. <i>Molecular Cell</i> , 2003, 11, 11-23.	9.7	723
2	Role for the p53 homologue p73 in E2F-1-induced apoptosis. <i>Nature</i> , 2000, 407, 645-648.	27.8	656
3	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	28.9	596
4	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. <i>Nature Genetics</i> , 2000, 25, 47-54.	21.4	479
5	Chemosensitivity linked to p73 function. <i>Cancer Cell</i> , 2003, 3, 403-410.	16.8	394
6	Neuroblastoma. <i>Pediatric Clinics of North America</i> , 2015, 62, 225-256.	1.8	328
7	A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. <i>Nature</i> , 2000, 407, 642-645.	27.8	309
8	VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail. <i>Molecular and Cellular Biology</i> , 2007, 27, 157-169.	2.3	230
9	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. <i>Nature Communications</i> , 2019, 10, 4343.	12.8	200
10	Viral Oncoproteins Discriminate between p53 and the p53 Homolog p73. <i>Molecular and Cellular Biology</i> , 1998, 18, 6316-6324.	2.3	179
11	Regulation of endocytosis via the oxygen-sensing pathway. <i>Nature Medicine</i> , 2009, 15, 319-324.	30.7	178
12	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3229-3241.	1.6	174
13	NEDD8 Pathways in Cancer, Sine Quibus Non. <i>Cancer Cell</i> , 2011, 19, 168-176.	16.8	156
14	Neuroblastoma Cells Isolated from Bone Marrow Metastases Contain a Naturally Enriched Tumor-Initiating Cell. <i>Cancer Research</i> , 2007, 67, 11234-11243.	0.9	155
15	Oncogenes Induce and Activate Endogenous p73 Protein. <i>Journal of Biological Chemistry</i> , 2001, 276, 11310-11316.	3.4	123
16	Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 4892-4897.	7.1	120
17	Association of <i>MYCN</i> copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>Cancer</i> , 2017, 123, 4224-4235.	4.1	97
18	Mdm2-mediated NEDD8 Modification of TAp73 Regulates Its Transactivation Function*. <i>Journal of Biological Chemistry</i> , 2006, 281, 34096-34103.	3.4	94

#	ARTICLE	IF	CITATIONS
19	Small Molecule Kinase Inhibitor Screen Identifies Polo-Like Kinase 1 as a Target for Neuroblastoma Tumor-Initiating Cells. <i>Cancer Research</i> , 2011, 71, 1385-1395.	0.9	92
20	Target and Agent Prioritization for the Children's Oncology Group's National Cancer Institute Pediatric MATCH Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	85
21	Suppression of Hypoxia-Inducible Factor 2 $\alpha$ Restores p53 Activity via Hdm2 and Reverses Chemoresistance of Renal Carcinoma Cells. <i>Cancer Research</i> , 2009, 69, 9056-9064.	0.9	77
22	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1084-1093.	6.3	73
23	Current and Future Strategies for Relapsed Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 337-347.	0.6	71
24	Tissue Microenvironment Modulates CXCR4 Expression and Tumor Metastasis in Neuroblastoma. <i>Neoplasia</i> , 2007, 9, 36-46.	5.3	69
25	Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. <i>Nature Medicine</i> , 2011, 17, 845-853.	30.7	68
26	In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model. <i>Neoplasia</i> , 2009, 11, 426-435.	5.3	67
27	Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. <i>Nature Communications</i> , 2019, 10, 224.	12.8	66
28	Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. <i>Oncotarget</i> , 2014, 5, 161-172.	1.8	65
29	Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. <i>EMBO Molecular Medicine</i> , 2010, 2, 371-384.	6.9	62
30	Clinical outcomes in children with adrenal neuroblastoma undergoing open versus laparoscopic adrenalectomy. <i>Journal of Pediatric Surgery</i> , 2013, 48, 1727-1732.	1.6	60
31	Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. <i>European Journal of Cancer</i> , 2016, 65, 1-10.	2.8	56
32	Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. <i>Cancer Research</i> , 2020, 80, 2663-2675.	0.9	55
33	Ubiquitin and Ubiquitin-Like Modifications of the p53 Family. <i>Neoplasia</i> , 2006, 8, 655-666.	5.3	54
34	Eukaryotic Translation Elongation Factor 1-Alpha 1 Inhibits p53 and p73 Dependent Apoptosis and Chemotherapy Sensitivity. <i>PLoS ONE</i> , 2013, 8, e66436.	2.5	54
35	Family Feud in Chemosensitivity: p73 and Mutant p53. <i>Cell Cycle</i> , 2004, 3, 317-321.	2.6	52
36	SATB2 augments p53 in head and neck squamous cell carcinoma. <i>EMBO Reports</i> , 2010, 11, 777-783.	4.5	50

#	ARTICLE	IF	CITATIONS
37	Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). <i>European Journal of Cancer</i> , 2019, 112, 66-79.	2.8	49
38	The challenge of defining "ultra-high-risk" neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27556.	1.5	43
39	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. <i>European Journal of Cancer</i> , 2020, 136, 52-68.	2.8	42
40	Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. <i>Journal of Clinical Oncology</i> , 2020, 38, 1906-1918.	1.6	41
41	<i>NRAS</i> Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma. <i>Cancer Research</i> , 2020, 80, 3413-3423.	0.9	40
42	The Human p73 Promoter: Characterization and Identification of Functional E2F Binding Sites. <i>Neoplasia</i> , 2002, 4, 195-203.	5.3	39
43	Pediatric oncology enters an era of precision medicine. <i>Current Problems in Cancer</i> , 2017, 41, 194-200.	2.0	39
44	Overexpressed TP73 induces apoptosis in medulloblastoma. <i>BMC Cancer</i> , 2007, 7, 127.	2.6	38
45	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 3506-3514.	1.6	38
46	Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2021, 22, 1764-1776.	10.7	37
47	Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 895-905.	2.1	36
48	Neuroblastoma: The impact of biology and cooperation leading to personalized treatments. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2012, 49, 85-115.	6.1	35
49	Characteristics and management of ganglioneuroma and ganglioneuroblastoma "intermixed" in children and adolescents. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26964.	1.5	35
50	Heterogeneity of <i>MYCN</i> amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 28-41.	2.8	34
51	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. <i>European Journal of Cancer</i> , 2021, 157, 198-213.	2.8	34
52	Genome-Wide DNA Methylation Analysis Reveals Epigenetic Dysregulation of MicroRNA-34A in <i>TP53</i> -Associated Cancer Susceptibility. <i>Journal of Clinical Oncology</i> , 2016, 34, 3697-3704.	1.6	33
53	Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. <i>Pediatric Blood and Cancer</i> , 2014, 61, 128-133.	1.5	31
54	Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27023.	1.5	31

#	ARTICLE	IF	CITATIONS
55	The Role of Surgery in High-risk Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, 1-7.	0.6	31
56	The ribosome-related protein, SBDS, is critical for normal erythropoiesis. <i>Blood</i> , 2011, 118, 6407-6417.	1.4	30
57	The ganglioside G <sub>D2</sub> as a circulating tumor biomarker for neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28031.	1.5	30
58	Analysis of needle versus open biopsy for the diagnosis of advanced stage pediatric neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2006, 47, 875-879.	1.5	29
59	A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28794.	1.5	29
60	Metastatic Neuroblastoma Confined to Distant Lymph Nodes (stage 4N) Predicts Outcome in Patients With Stage 4 Disease: A Study From the International Neuroblastoma Risk Group Database. <i>Journal of Clinical Oncology</i> , 2014, 32, 1228-1235.	1.6	28
61	A Metastatic Mouse Model Identifies Genes That Regulate Neuroblastoma Metastasis. <i>Cancer Research</i> , 2017, 77, 696-706.	0.9	28
62	Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1636-1641.	1.5	27
63	Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1508-1515.	3.5	27
64	Family feud in chemosensitivity: p73 and mutant p53. <i>Cell Cycle</i> , 2004, 3, 319-23.	2.6	27
65	Surveillance imaging and radiation exposure in the detection of relapsed neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1786-1793.	1.5	24
66	Inhibition of SRC Corrects GM-CSF Hypersensitivity That Underlies Juvenile Myelomonocytic Leukemia. <i>Cancer Research</i> , 2013, 73, 2540-2550.	0.9	23
67	Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. <i>JAMA Oncology</i> , 2021, 7, 1806.	7.1	22
68	The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. <i>Nature Communications</i> , 2021, 12, 6274.	12.8	22
69	Retrospective evaluation of a decision support algorithm (MIPOGC) for genetic referrals for children with neuroblastic tumors. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27390.	1.5	21
70	Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-15.	2.1	20
71	p53 family: therapeutic targets in neuroblastoma. <i>Future Oncology</i> , 2010, 6, 429-444.	2.4	18
72	Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 222-227.	0.6	17

#	ARTICLE	IF	CITATIONS
73	Veno-occlusive disease after high-dose busulfan and melphalan in neuroblastoma. Bone Marrow Transplantation, 2020, 55, 531-537.	2.4	17
74	An upfront immunomodulatory therapy protocol for pediatric opsoclonus-myoclonus syndrome. Pediatric Blood and Cancer, 2019, 66, e27776.	1.5	16
75	Bridging the Distance in the Caribbean: Telemedicine as a means to build capacity for care in paediatric cancer and blood disorders. Studies in Health Technology and Informatics, 2015, 209, 1-8.	0.3	15
76	Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project. European Journal of Cancer, 2012, 48, 1185-1191.	2.8	14
77	Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma. Molecular Oncology, 2016, 10, 1461-1472.	4.6	14
78	Long-term hepatic outcomes in survivors of stage 4S and 4 neuroblastoma in infancy. Pediatric Blood and Cancer, 2012, 58, 283-288.	1.5	13
79	Natural course of low risk neuroblastoma. Pediatric Blood and Cancer, 2012, 58, 690-694.	1.5	13
80	Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. Pediatric Blood and Cancer, 2016, 63, 1019-1023.	1.5	13
81	Incidence and Prognostic Role of the Ocular Manifestations of Neuroblastoma in Children. American Journal of Ophthalmology, 2020, 213, 145-152.	3.3	13
82	Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group. European Journal of Cancer, 2020, 133, 112-119.	2.8	13
83	Surgical challenges associated with intensive treatment protocols for high-risk neuroblastoma. Journal of Pediatric Surgery, 2006, 41, 960-965.	1.6	11
84	Special AT-rich Binding Protein-2 (SATB2) Differentially Affects Disease-causing p63 Mutant Proteins. Journal of Biological Chemistry, 2011, 286, 40671-40680.	3.4	11
85	Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).. Journal of Clinical Oncology, 2020, 38, 10505-10505.	1.6	11
86	Long term outcomes after concurrent ipsilateral nephrectomy versus kidney-sparing surgery for high-risk, intraabdominal neuroblastoma. Journal of Pediatric Surgery, 2019, 54, 1632-1637.	1.6	9
87	Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration. Cell Reports, 2021, 36, 109363.	6.4	9
88	<sup>223</sup> Rn: Misunderstood protein?. Cancer Biology and Therapy, 2006, 5, 804-807.	3.4	7
89	Metachronous Neuroblastoma in an Infant With Germline Translocation Resulting in Partial Trisomy 2p. Journal of Pediatric Hematology/Oncology, 2014, 36, e193-e196.	0.6	7
90	The neuroblastoma and ganglion components of nodular ganglioneuroblastoma are genetically similar: evidence against separate clonal origins. Modern Pathology, 2015, 28, 166-176.	5.5	5

#	ARTICLE	IF	CITATIONS
91	Advancing Clinicopathologic Diagnosis of High-risk Neuroblastoma Using Computerized Image Analysis and Proteomic Profiling. <i>Pediatric and Developmental Pathology</i> , 2017, 20, 394-402.	1.0	5
92	Diagnostic practices and disease surveillance in Canadian children with congenital central hypoventilation syndrome. <i>Canadian Respiratory Journal</i> , 2013, 20, 165-170.	1.6	4
93	Measuring primary tumor response in neuroblastoma: More than using a ruler. <i>Pediatric Blood and Cancer</i> , 2017, 64, 11-12.	1.5	4
94	<scp>COVID</scp> â€19: a pandemic experience that illuminates potential reforms to health research. <i>EMBO Molecular Medicine</i> , 2020, 12, e13278.	6.9	4
95	Autologous stem cell transplantation for refractory opsoclonus myoclonus ataxia syndrome. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27110.	1.5	3
96	Tandem Transplant for High-Risk Neuroblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 729.	7.4	3
97	Theranostics in Neuroblastoma. <i>PET Clinics</i> , 2021, 16, 419-427.	3.0	3
98	G<sub>D2</sub> as a circulating tumor biomarker (CTB) for neuroblastoma (NBL).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10538-10538.	1.6	2
99	Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10500-10500.	1.6	2
100	Temporal clustering of neuroblastic tumours in children and young adults from Ontario, Canada. <i>Environmental Health</i> , 2022, 21, 30.	4.0	2
101	Current and Future Strategies for Treatment of Relapsed Neuroblastoma. , 2019, , 263-281.		1
102	Regulatory oversight for research tests and laboratory-developed diagnostics should be more nimble. <i>Cmaj</i> , 2019, 191, E1388-E1388.	2.0	1
103	Crizotinib response in a neuroblastoma patient with a constitutional mosaic anaplastic lymphoma kinase 1170Nâ€activating mutation. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28916.	1.5	1
104	Residual metaâ€iodobenzyl guanidine (MIBG) positivity following therapy for metastatic neuroblastoma: Patient characteristics, imaging, and outcome. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29289.	1.5	1
105	A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10012-10012.	1.6	1
106	Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma. <i>Molecular Cancer Research</i> , 2022, 20, 895-908.	3.4	1
107	Abstract 5224: The PRrecision Oncology For Young peopLE (PROFYLE) Program: A national precision oncology program for children, adolescents and young adults with hard-to-cure cancer in Canada. <i>Cancer Research</i> , 2022, 82, 5224-5224.	0.9	1
108	Reply to K. Beiske et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 3720-3721.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) to predict outcome in patients with stage 4 disease: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database.. Journal of Clinical Oncology, 2013, 31, 10015-10015.	1.6	0
110	Spy'ing on differentiation in neuroblastoma. Oncotarget, 2014, 5, 5848-5849.	1.8	0
111	The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients. Oncotarget, 2018, 9, 10698-10713.	1.8	0
112	Predictors of differential response to induction chemotherapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).. Journal of Clinical Oncology, 2018, 36, 10532-10532.	1.6	0
113	Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients 18 months with unfavorable histology and without MYCN amplification: A Children's Oncology Group (COG) report.. Journal of Clinical Oncology, 2020, 38, 10502-10502.	1.6	0
114	Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children's Oncology Group (COG) risk stratification.. Journal of Clinical Oncology, 2022, 40, 10013-10013.	1.6	0